Navigation Links
Dartmouth researchers identify potential therapeutic target for deadly brain cancer
Date:4/8/2014

(Lebanon, NH, 4/8/14) Researchers from the Geisel School of Medicine at Dartmouth will present a scientific poster on Tuesday, April 8, 2014 at the American Association of Cancer Researchers conference in San Diego, CA. The research identifies a potential characteristic for predicting outcome in a deadly form of brain cancer known as glioblastoma multiforme.

Existing therapies based on genetic information have failed to effectively treat glioblastomas. Therefore, researchers are aggressively looking to find new molecular targets for this aggressive brain tumor.

Dartmouth researchers previously demonstrated that STK17A is a protein that is induced when DNA is damaged by the chemotherapeutic drug cisplatin. Biopsied samples of glioblastoma tumors contain high level of STK17A. And the more STK17A a tumor has the poorer the outcome appears to be. Increased levels of STK17A are correlated with shorter survival time for glioblastoma patients.

In addition, when researchers tried to "turn off" the STK17A protein, they observed a reduced rate of cancer cell growth. Reducing STK17A also interfered with tumor cells' ability to move around and invade other areas of the brain.

Further investigation is required to understand the precise role of STK17A in glioblastoma, but the finding may reveal a potential Achilles' Heel for this deadly type of brain tumor that often times seems unstoppable.


'/>"/>

Contact: Robin Dutcher
robin.Dutcher@hitchcock.org
603-653-9056
The Geisel School of Medicine at Dartmouth
Source:Eurekalert

Page: 1

Related biology news :

1. Dartmouth researchers find promising results with local hyperthermia of tumors
2. Dartmouth-led research shows temperature, not snowfall, driving tropical glacier size
3. Dartmouth study shows US Southwest irrigation system facing decline after 4 centuries
4. Dartmouth researchers develop new tool to identify genetic risk factors
5. Dartmouth-led team gets $8 million grant to research arsenic in children
6. Dartmouth-led study shows diet alone can be significant source of arsenic
7. Dartmouth-led team discovers how plants avoid sunburn
8. Dartmouth researchers find there is no single sexy chin
9. Dartmouth researchers invent real time secondhand smoke sensor
10. Dartmouth neuroscientist finds free will has neural basis
11. Dartmouth research offers new control strategies for bipolar bark beetles
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:3/20/2017)... 20, 2017 At this year,s CeBIT Chancellor Dr. ... manufacturer DERMALOG. The Chancellor came to the DERMALOG stand together with the ... year,s CeBIT partner country. At the largest German biometrics company the two ... face and iris recognition as well as DERMALOGĀ“s multi-biometrics system.   ... ...
(Date:3/16/2017)... -- CeBIT 2017 - Against identity fraud with DERMALOG solutions "Made in ... ... Used combined in one project, multi-biometric solutions provide a crucial contribution against identity fraud. (PRNewsFoto/Dermalog ... Used combined in one project, multi-biometric solutions provide ... ...
(Date:3/9/2017)... , March 9, 2017 4Dx has publicly ... Lung Imaging Workshop at the University of Pennsylvania. Founder ... to deliver the latest data to world leaders in ... brings together leaders at the forefront of the industry ... imaging. "The quality of the imaging ...
Breaking Biology News(10 mins):
(Date:3/23/2017)... ... March 23, 2017 , ... AxioMed ... both viscous and elastic characteristics when deformed, which is identical to how the ... gently absorb compressive forces and return to its natural state along a hysteresis ...
(Date:3/23/2017)... March 23, 2017  Northwest Biotherapeutics (OTCQB: NWBO) ... immune therapies for solid tumor cancers, today announced ... financing it announced last Friday, March 17, 2017. ... institutional investors securities totaling 28,843,692 shares, comprised of ... 10,000,000 shares of Class C Warrants pre-funded at ...
(Date:3/23/2017)... 2017  BioPharmX Corporation (NYSE MKT: BPMX), a ... market, today reported financial results for the quarter ... provide an update on the company,s clinical development ... "We are pleased to report that last year ... President Anja Krammer. "We achieved key clinical milestones ...
(Date:3/23/2017)... YORK , March 23, 2017 ... ... of death, putting significant strain on health care systems, in ... cancer diagnoses rises, so too does the development of innovative ... minimum side effects. Among the many types of cancer treatments, ...
Breaking Biology Technology: